Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)
Condition: Hodgkin Lymphoma Intervention: Drug: Nivolumab Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials